Rocuronium
Depends on presentation or useFull monograph review pending
U.S. label preparation
Rocuronium bromide injection · Depends on presentation or use
- Preparation
- The 10 mg/mL injection can be given as an IV bolus. For admixtures the label documents concentrations up to 5 mg/mL in compatible fluids, including 0.9% sodium chloride or 5% dextrose.
- Administration and handling
- Neuromuscular blockade requires adequate anesthesia or sedation, ventilatory support and neuromuscular monitoring. Check the label for line incompatibilities.
- Manufacturer's storage limits
- The label describes up to 24 hours at room temperature after mixing in specified plastic bags, glass bottles or plastic syringe pumps. A compounding beyond-use date requires a separate assessment.
Product and source details
HF Acquisition Co LLC, DBA HealthFirst · ANDA206206
Product NDC: 51662-1545
SPL effective 2022-04-09 | SPL version 1. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.